Fig. 6: P-tau212 performance in plasma versus CSF to distinguish Aβ + AD from Aβ- controls. | Nature Communications

Fig. 6: P-tau212 performance in plasma versus CSF to distinguish Aβ + AD from Aβ- controls.

From: Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology

Fig. 6

The plots in a and b show p-tau212 levels in Aβ-positive AD (n = 74) participants compared with Aβ-negative controls (n = 21) in paired plasma and CSF samples respectively in the Polish cohort. c AUCs of the accuracies of p-tau212 in plasma versus CSF to separate the groups shown in (a) and (b). De Long’s test comparing the AUCs for plasma and CSF p-tau212 did not reach statistical significance. d Plasma p-tau212 levels in Aβ-positive AD (n = 16) participants compared with Aβ-negative controls (n = 14) in the Gothenburg cohort. e Comparison of the AUC values for plasma p-tau212 versus those for plasma p-tau231 and p-tau181 in the same set of samples shown in (d). Box plots are shown as median and interquartile range (IQR), boundaries of the whiskers are minimum and maximum values. Group differences were examined using two-tailed Mann–Whitney test. The Polish cohort included individuals with paired CSF and EDTA plasma samples (n = 95) from Erlangen Score defined controls (n = 21) and AD (n = 74). The Gothenburg discovery cohort (n = 30) included EDTA plasma samples from neurochemically defined Alzheimer’s disease participants (n = 16) and controls (n = 14). Source data are provided as a Source Data file.

Back to article page